Company profile: OLM Diagnostics
1.1 - Company Overview
Company description
- Provider of fungal and bacterial diagnostic solutions for healthcare providers, including: AspLFD, a lateral flow device detecting Aspergillus antigens in 15–40 minutes; AspID and PneumID real-time PCR kits for Aspergillus species (90 minutes) and Pneumocystis jirovecii (45 minutes); CandID for early Candida bloodstream detection; and AurisID for identifying Candida auris.
Products and services
- AspID: A real-time PCR kit identifying clinically relevant Aspergillus species from various sample types, delivering results within 90 minutes for rapid species determination in fungal diagnostics
- AspLFD: A lateral flow device detecting Aspergillus-specific antigens from serum and bronchoalveolar lavage fluid, producing results in 15–40 minutes for rapid antigen detection
- PneumID: A real-time PCR kit detecting Pneumocystis jirovecii from bronchoalveolar lavage and respiratory wash samples, offering results within 45 minutes for prompt respiratory pathogen identification
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OLM Diagnostics
Lumos Diagnostics
HQ: United States
Website
- Description: Provider of rapid point-of-care diagnostic solutions, including customized assay development, full-scale contract manufacturing for lateral flow strips and readers, proprietary digital reader platforms, companion apps, and cloud connectivity for data capture and visualization, supported by in-house clinical study design, site management, and regulatory affairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumos Diagnostics company profile →
Entasis Therapeutics
HQ: United States
Website
- Description: Provider of anti-infective therapies for serious drug-resistant bacterial infections. Products include GIAPREZA (angiotensin II to increase blood pressure in septic or distributive shock), XERAVA (eravacycline for complicated intra-abdominal infections), XACDURO (sulbactam/durlobactam for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex), and zoliflodacin (Phase 3 for uncomplicated gonorrhea).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Entasis Therapeutics company profile →
Anaconda Pharma
HQ: France
Website
- Description: Provider of biopharmaceutical R&D focused on developing treatments for infections by human papillomavirus (HPV). Privately held, incorporated in November 2003, operating from lab space within the BioTop incubator at the Pasteur Institute campus in Paris, France.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anaconda Pharma company profile →
ISR Immune System Regulation
HQ: Sweden
Website
- Description: Provider of innovation-driven immunotherapy research, conducting preclinical and clinical studies to develop novel drugs for curative treatment of viral infections, based at the Karolinska Hospital in Stockholm, Sweden.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ISR Immune System Regulation company profile →
Protez Pharmaceuticals
HQ: United States
Website
- Description: Provider of differentiated intravenous and oral small molecule antibiotics for difficult-to-treat hospital-based infections, addressing bacterial resistant and chronic or recurrent infections; discovers, develops, and commercializes antibiotic therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protez Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OLM Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OLM Diagnostics
2.2 - Growth funds investing in similar companies to OLM Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OLM Diagnostics
4.2 - Public trading comparable groups for OLM Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →